Propanc Biopharma, Inc.(PPCB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PPCB Propanc Biopharma, Inc.

交易中 09-25 13:49:36 EDT

0.6599

+0.0581

+9.65%

最高0.6698	最低0.5910	成交量34.01万
今开0.5911	昨收0.6018	日振幅13.09%
总市值231.17万	流通市值82.49万	总股本350.31万
成交额21.70万	换手率27.21%	流通股本125.01万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":0.6599,"timestamp":1790358188605,"preClose":0.6018,"halted":0,"volume":340124,"delay":0,"changeRate":0.09654370222665344,"floatShares":1250100,"shares":3503100,"eps":-32.455997,"marketStatus":"交易中","change":0.0581,"latestTime":"09-25 13:49:36 EDT","open":0.5911,"high":0.6698,"low":0.591,"amount":216996.08489640002,"amplitude":0.130941,"askPrice":0.6598,"askSize":100,"bidPrice":0.62,"bidSize":8,"shortable":0,"etf":0,"ttmEps":-32.455997,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790366400000},"marketStatusCode":2,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":0.6018,"preHourTrading":{"tag":"盘前","latestPrice":0.6,"preClose":0.6018,"latestTime":"09:17 EDT","volume":42063,"amount":26944.02460365,"timestamp":1790342278436,"change":-0.0018,"changeRate":-0.002991,"amplitude":0.098039},"postHourTrading":{"tag":"盘后","latestPrice":0.6018,"preClose":0.6018,"latestTime":"19:57 EDT","volume":2099,"amount":1273.6583,"timestamp":1790294250280,"change":0,"changeRate":0,"amplitude":0.045696},"volumeRatio":2.283995},"requestUrl":"/m/hq/s/PPCB","defaultTab":"news","newsList":[{"id":"1145921717","title":"Propanc Biopharma计划开展1B期临床研究，拟纳入40-45名晚期实体瘤患者，临床试验申请预计数月内提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1145921717","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145921717?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:32","pubTimestamp":1787833930,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司宣布，其计划推进一项1B期临床研究，该研究拟招募40至45名患有晚期实体瘤的患者。据公司透露，相关临床试验申请预计将在未来数月内正式递交。通过这项研究，Propanc Biopharma旨在进一步评估其候选药物的安全性和初步疗效，为后续更大规模的临床开发奠定基础。随着申请日期的临近，业界将密切关注监管机构的反馈以及该研究的后续进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188382612","title":"Propanc Biopharma公布PRP新型临床前胰腺癌数据：肿瘤生长抑制率超90%，生存获益逾2.5倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1188382612","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188382612?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:31","pubTimestamp":1787833890,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 近日揭晓了一项针对其候选药物PRP的临床前研究新成果，数据令人瞩目。研究显示，该药物在胰腺癌模型中展现出强劲的抗肿瘤活性，肿瘤生长抑制率突破90%大关，同时将实验对象的生存期延长了2.5倍以上。这一发现为胰腺癌这一难治性肿瘤的治疗策略带来了新的曙光。Propanc Biopharma表示，团队正加速评估这些数据，并规划后续的研发路径，以期尽快将这一潜在疗法惠及全球患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159793711","title":"Propanc Biopharma宣布PRP在胰腺导管腺癌模型中展现超90%肿瘤生长抑制及显著生存获益的积极临床前与早期转化数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1159793711","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159793711?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:37","pubTimestamp":1786019874,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 近日公布了其核心候选药物PRP的积极临床前和早期转化研究结果。在胰腺导管腺癌（PDAC）模型中，PRP显示出超过90%的肿瘤生长抑制率，并显著延长了实验对象的生存期。这一里程碑式的数据，为后续的临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136433126","title":"Propanc Biopharma, Inc.将在澳大利亚提交CTA，启动针对30-40名晚期癌症患者的1B期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1136433126","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136433126?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:46","pubTimestamp":1779281202,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 计划在澳大利亚提交临床试验申请，旨在启动一项涉及30至40名晚期癌症患者的1B期研究。这一举措标志着该公司在推进其新型癌症治疗方案的临床开发道路上迈出了关键一步。在澳大利亚提交CTA的决定，反映了公司利用该国高效监管框架和强大临床研究生态系统的战略考量。成功完成此阶段研究，有望为Propanc Biopharma, Inc.的核心产品管线带来重要的价值提升，并为其针对难治性癌症的开发策略提供关键支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186690041","title":"Propanc Biopharma公司计划开展两项II期研究，针对胰腺癌和卵巢癌各招募60名患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1186690041","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186690041?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:46","pubTimestamp":1779281199,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司宣布，将启动两项独立的II期临床研究，分别针对胰腺癌和卵巢癌患者。据悉，每项研究计划招募60名参与者，以评估其候选疗法的安全性与有效性。这一举措标志着该公司在推进其肿瘤治疗管线方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158942593","title":"Propanc Biopharma实施并股计划，以维系纳斯达克上市地位并推进增长战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1158942593","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158942593?lang=zh_cn&edition=full","pubTime":"2026-05-14 10:00","pubTimestamp":1778724015,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司已正式执行反向股票分割（并股）方案。此举旨在满足纳斯达克资本市场持续上市的最低股价要求，从而稳固其上市地位。同时，公司期望这一资本结构调整能为其既定的长期业务增长与拓展计划提供更坚实的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118487671","title":"Propanc Biopharma公司提交文件，计划由售股股东转售最多1500万股普通股——SEC备案披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1118487671","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118487671?lang=zh_cn&edition=full","pubTime":"2026-04-11 05:33","pubTimestamp":1775856802,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司已向美国证券交易委员会提交相关文件，内容涉及一项由售股股东发起的普通股转售计划。根据备案信息，该计划拟转售的普通股数量最高可达1500万股。\n此次提交标志着售股股东可能将在公开市场进行大规模股份出售。相关细节已在SEC备案中列明，市场将密切关注此举对公司股权结构及二级市场股价的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.propanc.com","stockEarnings":[{"period":"1week","weight":-0.0448},{"period":"1month","weight":-0.4674},{"period":"3month","weight":-0.5906},{"period":"6month","weight":-0.7667},{"period":"1year","weight":-0.9876},{"period":"ytd","weight":-0.9551}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.2099},{"period":"1year","weight":0.1605},{"period":"ytd","weight":0.125}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Propanc Biopharma, Inc.最初于2007年10月15日在澳大利亚维多利亚州墨尔本成立。2010年11月23日，该公司在特拉华州重新注册并重新注册。他们是一家发展阶段的医疗保健公司，目前专注于为患有胰腺癌、卵巢癌和癌症的患者开发新的癌症治疗方法。利用他们的科学和肿瘤学顾问，他们开发了一种合理的抗癌化合物复合配方，这些化合物共同发挥多种作用，旨在控制或防止肿瘤在体内复发和扩散。他们的主要候选产品PRP是他们新配方的变体，涉及酶原，即酶的无活性前体。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.35863},{"month":2,"riseRate":0,"avgChangeRate":-0.3412},{"month":3,"riseRate":0,"avgChangeRate":-0.231595},{"month":4,"riseRate":0,"avgChangeRate":-0.393912},{"month":5,"riseRate":0.25,"avgChangeRate":-0.125956},{"month":6,"riseRate":0.5,"avgChangeRate":0.512759},{"month":7,"riseRate":0.2,"avgChangeRate":-0.081258},{"month":8,"riseRate":0.25,"avgChangeRate":-0.277509},{"month":9,"riseRate":0,"avgChangeRate":-0.449216},{"month":10,"riseRate":0,"avgChangeRate":-0.267792},{"month":11,"riseRate":0,"avgChangeRate":-0.325477},{"month":12,"riseRate":0.25,"avgChangeRate":-0.177784}],"exchange":"NASDAQ","name":"Propanc Biopharma, Inc.","nameEN":"Propanc Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Propanc Biopharma, Inc.(PPCB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Propanc Biopharma, Inc.(PPCB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Propanc Biopharma, Inc.,PPCB,Propanc Biopharma, Inc.股票,Propanc Biopharma, Inc.股票老虎,Propanc Biopharma, Inc.股票老虎国际,Propanc Biopharma, Inc.行情,Propanc Biopharma, Inc.股票行情,Propanc Biopharma, Inc.股价,Propanc Biopharma, Inc.股市,Propanc Biopharma, Inc.股票价格,Propanc Biopharma, Inc.股票交易,Propanc Biopharma, Inc.股票购买,Propanc Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Propanc Biopharma, Inc.(PPCB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Propanc Biopharma, Inc.(PPCB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}